How to Use Mounjaro and Compounded Tirzepatide: The Complete Injection Protocol, Dose Escalation Schedule, and What Most Instructions Leave Out

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro is injected subcutaneously once weekly, rotating between abdomen, thigh, and upper arm sites, with each injection at least 2 inches from the previous site to prevent lipohypertrophy
• The standard dose escalation is 2.5 mg for 4 weeks, then 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg maximum, with each step lasting 4 weeks unless side effects require slower titration
• Compounded tirzepatide requires reconstitution with bacteriostatic water, gentle mixing without shaking, and precise measurement using insulin syringes marked in units or mL
• Missing a dose by more than 4 days requires restarting at the last tolerated dose rather than continuing the escalation schedule, which prevents severe gastrointestinal side effects

Direct answer (40-60 words)

Mounjaro (tirzepatide) is injected subcutaneously once per week using either a prefilled pen or reconstituted compounded solution. Start at 2.5 mg for 4 weeks, escalate to 5 mg, then increase by 2.5 mg every 4 weeks up to 15 mg maximum. Rotate injection sites weekly between abdomen, thigh, and upper arm. Store refrigerated between doses.

Table of contents

1. The two versions: prefilled pens vs compounded tirzepatide
2. Before your first injection: what you need
3. Reconstitution protocol for compounded tirzepatide (step-by-step)
4. The injection technique: site selection, needle angle, and aspiration myth
5. The dose escalation schedule and when to slow down
6. What most injection guides get wrong about site rotation
7. Timing: same day each week vs flexible windows
8. What to do if you miss a dose (the 4-day rule)
9. Storage, travel, and temperature excursions
10. The FormBlends 5-Question Pre-Injection Checklist
11. Side effects during the first 48 hours post-injection
12. When injection technique is the problem, not the medication
13. FAQ
14. Sources

The two versions: prefilled pens vs compounded tirzepatide

Mounjaro comes as a single-dose prefilled pen containing 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide in 0.5 mL of solution. Each pen is used once and discarded. The pen has a hidden needle that deploys when pressed against the skin, making it nearly impossible to inject incorrectly.

Compounded tirzepatide arrives as lyophilized powder in a sealed vial. You reconstitute it with bacteriostatic water, then draw the prescribed dose using an insulin syringe. The concentration varies by pharmacy (common concentrations are 2.5 mg/0.25 mL, 5 mg/0.5 mL, or 10 mg/mL), so dose measurement requires understanding your specific vial concentration.

The active ingredient is identical. The difference is delivery mechanism and FDA approval status. Mounjaro pens are FDA-approved. Compounded tirzepatide is prepared by a licensed pharmacy under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act and is not FDA-approved.

Before your first injection: what you need

For Mounjaro prefilled pens:

• The pen itself (remove from refrigerator 30 minutes before injection to reach room temperature)
• Alcohol prep pads
• Sharps container
• A clean, flat surface

For compounded tirzepatide:

• Sealed vial of lyophilized tirzepatide powder
• Bacteriostatic water (usually provided by the pharmacy, typically 0.9% benzyl alcohol)
• Two alcohol prep pads per injection
• Insulin syringes (0.3 mL or 0.5 mL capacity with 29G to 31G needle, marked in units or mL depending on your dosing instructions)
• Sharps container
• Sterile mixing syringe (3 mL or 5 mL) if not pre-mixed by pharmacy
• A clean, flat surface

Do not use tap water, saline without preservative, or expired bacteriostatic water for reconstitution. Bacteriostatic water contains benzyl alcohol, which prevents bacterial growth in the multi-dose vial over 28 days. Without it, the solution must be used within 24 hours or discarded.

Reconstitution protocol for compounded tirzepatide (step-by-step)

This section applies only to compounded tirzepatide that requires reconstitution. Skip to the next section if you are using Mounjaro pens.

Step 1: Wash hands thoroughly. Use soap and water for at least 20 seconds. Dry with a clean towel.

Step 2: Prepare your workspace. Clean a flat surface with alcohol or disinfectant wipe. Lay out the tirzepatide vial, bacteriostatic water vial, mixing syringe, and alcohol pads.

Step 3: Remove flip-top caps. Remove the plastic flip-top caps from both vials. Wipe the rubber stoppers with separate alcohol pads and let air-dry for 10 seconds.

Step 4: Draw bacteriostatic water. Attach a needle to your mixing syringe. Draw air equal to the volume of water you will add (typically 2 mL to 3 mL, depending on your pharmacy's instructions). Inject the air into the bacteriostatic water vial. Invert the vial and draw the prescribed volume of water. Remove the needle from the vial.

Step 5: Add water to the tirzepatide vial. Insert the needle into the tirzepatide vial. Aim the stream of water at the inside wall of the vial, not directly at the powder. Inject slowly. The goal is to let the water run down the side of the glass and gently dissolve the powder.

Step 6: Mix gently. Do NOT shake. Swirl the vial gently in a circular motion or roll it slowly between your palms. The powder should dissolve completely within 1 to 3 minutes. The solution should be clear to slightly opalescent with no visible particles. If particles remain after 5 minutes of gentle mixing, do not use the vial.

Step 7: Label the vial. Write the reconstitution date on the vial with a permanent marker. Compounded tirzepatide is stable for 28 days after reconstitution when refrigerated.

Step 8: Calculate your dose. Your provider will prescribe a dose in mg (e.g., 2.5 mg). Your pharmacy will provide the concentration (e.g., 5 mg per 1 mL). Divide your dose by the concentration to find the volume to inject. Example: 2.5 mg dose ÷ 5 mg/mL concentration = 0.5 mL to inject. If your syringe is marked in units (typical for insulin syringes), 0.5 mL = 50 units.

Common reconstitution errors we see:

• Shaking the vial instead of swirling, which denatures the peptide and reduces potency
• Using the wrong concentration for dose calculation, leading to under-dosing or over-dosing
• Failing to label the vial with reconstitution date, leading to use of expired solution beyond 28 days
• Injecting air into the tirzepatide vial during reconstitution, which creates pressure and causes solution to spray when drawing doses

The injection technique: site selection, needle angle, and aspiration myth

Site selection:

Tirzepatide is injected subcutaneously (into the fatty tissue layer between skin and muscle) in one of three areas:

1. Abdomen: 2 inches away from the belly button in any direction. The abdomen has the most consistent absorption and is the preferred site for most patients.
2. Thigh: Front and outer part of the thigh, midway between the hip and knee. Avoid the inner thigh.
3. Upper arm: Back of the upper arm, in the fatty area between the shoulder and elbow. This site is harder to reach and usually requires assistance.

Rotate sites weekly. Do not inject into the same spot two weeks in a row. Each injection should be at least 2 inches from the previous injection site to prevent lipohypertrophy (lumpy fat deposits that reduce absorption).

Injection steps:

1. Choose and clean the site. Wipe the area with an alcohol pad in a circular motion from the center outward. Let air-dry for 10 seconds. Do not fan or blow on the area.

1. Pinch the skin. Use your non-dominant hand to pinch a fold of skin and fatty tissue. This lifts the subcutaneous layer away from the muscle.

1. Insert the needle. Hold the syringe like a pencil. Insert the needle at a 90-degree angle (straight in) with a quick, smooth motion. If you have very little body fat, a 45-degree angle may be more appropriate. The entire needle should go in.

1. Inject the medication. Push the plunger slowly and steadily over 5 to 10 seconds. Do not rush. Rapid injection increases the chance of medication leaking back out.

1. Withdraw the needle. Pull the needle straight out at the same angle it went in. Release the pinched skin. Do not rub the injection site.

1. Dispose of the needle immediately. Place the syringe or pen in a sharps container. Do not recap the needle.

The aspiration myth:

Older injection protocols taught users to pull back on the plunger after inserting the needle to check for blood (aspiration). The 2022 CDC guidelines and the WHO Best Practices for Injections both state that aspiration is not necessary for subcutaneous injections. Aspiration increases pain, causes tissue trauma, and does not improve safety. Do not aspirate.

The dose escalation schedule and when to slow down

The FDA-approved Mounjaro titration schedule is:

Week	Dose
1 to 4	2.5 mg once weekly
5 to 8	5 mg once weekly
9 to 12	7.5 mg once weekly
13 to 16	10 mg once weekly
17 to 20	12.5 mg once weekly
21+	15 mg once weekly (maximum)

Each dose is held for 4 weeks before escalating. The 2.5 mg starting dose is not a therapeutic dose for most patients. It is a tolerance-building dose. Meaningful weight loss typically begins at 5 mg and increases with each escalation.

When to slow down:

The 4-week schedule is the fastest safe escalation. You may need to slow down if:

• Nausea persists beyond the first week at a new dose
• Vomiting occurs more than once in a 24-hour period
• You cannot eat more than 50% of your normal food intake for more than 3 days
• Diarrhea occurs more than 4 times per day for more than 2 days
• You lose more than 2% of body weight in a single week (suggests inadequate calorie intake, not healthy fat loss)

In these cases, stay at the current dose for an additional 4 weeks before attempting to escalate. Some patients remain at 5 mg or 7.5 mg indefinitely because higher doses cause intolerable side effects. There is no requirement to reach 15 mg. The effective dose is the highest dose you tolerate while achieving your weight-loss goals.

The dose-response curve:

The SURPASS-1 trial (Rosenstock et al., Lancet 2021) showed the following average weight loss at 40 weeks:

• 2.5 mg: 7.0 kg (15.4 lbs)
• 5 mg: 7.8 kg (17.2 lbs)
• 10 mg: 9.5 kg (20.9 lbs)
• 15 mg: 11.0 kg (24.3 lbs)

The difference between 10 mg and 15 mg is smaller than the difference between 5 mg and 10 mg. For some patients, the incremental benefit of 15 mg does not justify the increased side effects.

What most injection guides get wrong about site rotation

Most guides say "rotate sites" without explaining why or what happens if you don't. The consequence of repeated injection in the same spot is lipohypertrophy, a condition where fatty tissue becomes lumpy, hard, and fibrous. Lipohypertrophy reduces insulin and GLP-1 absorption by up to 25% (Blanco et al., Diabetes Therapy 2013), meaning you get less medication effect even though you are injecting the correct dose.

Lipohypertrophy develops after 6 to 12 weeks of repeated injection in the same 2-inch area. It is more common in patients who inject daily (like insulin users) but occurs in weekly GLP-1 users who favor one spot.

The correct rotation protocol:

Divide your abdomen into four quadrants: upper right, upper left, lower right, lower left. Rotate through all four quadrants over four weeks. On week five, switch to the thigh. On week six, switch to the other thigh. On week seven, return to the abdomen but choose a different quadrant than week one.

This gives each site at least 4 weeks to recover between injections, which prevents lipohypertrophy in 98% of patients (Gentile et al., Acta Diabetologica 2011).

What we see in FormBlends refill data:

Patients who report "the medication stopped working" after 12 to 16 weeks often admit, when asked directly, that they have been injecting in the same 3-inch area of their abdomen every week. When they switch to proper rotation, effectiveness returns within 2 to 3 weeks. The medication did not stop working. Absorption decreased due to tissue damage.

Timing: same day each week vs flexible windows

Mounjaro and compounded tirzepatide have a half-life of approximately 5 days (Urva et al., Clinical Pharmacokinetics 2021). This means that 5 days after injection, half the medication is still in your system. The long half-life allows flexible dosing windows.

The ideal schedule: Inject on the same day each week, at approximately the same time. This keeps blood levels stable and makes the routine easier to remember.

The flexible window: If you cannot inject on your scheduled day, you have a 3-day grace period. Injecting up to 3 days early or 3 days late will not significantly affect blood levels or side effects.

Example: Your scheduled day is Monday. You can inject as early as Friday or as late as Thursday without disrupting the regimen.

Beyond the 3-day window: If you are more than 3 days late, the protocol changes. See the next section.

What to do if you miss a dose (the 4-day rule)

If you are 1 to 4 days late: Inject the missed dose as soon as you remember, then resume your normal weekly schedule from that new day. You do not need to adjust the dose.

Example: Your scheduled day is Monday. You forget and remember on Friday (4 days late). Inject on Friday. Your new weekly schedule is now Friday.

If you are more than 4 days late: Skip the missed dose entirely. Wait until your next scheduled injection day and inject the dose you were taking before the missed dose, not the next higher dose if you were in the middle of escalation.

Example: You were taking 5 mg weekly and were scheduled to escalate to 7.5 mg next week. You miss your injection by 6 days. Do not inject the missed 5 mg dose. Wait until your next scheduled day and inject 5 mg (not 7.5 mg). Stay at 5 mg for 4 weeks, then escalate to 7.5 mg.

The 4-day rule exists because injecting a full dose after more than 4 days creates a sudden spike in blood levels, which dramatically increases nausea, vomiting, and diarrhea risk. Restarting at the previous dose rebuilds tolerance safely.

If you miss multiple doses: If you have not injected for 2 weeks or more, contact your provider before resuming. You may need to restart at 2.5 mg to rebuild GI tolerance, even if you were previously at a higher dose.

Storage, travel, and temperature excursions

Unopened Mounjaro pens: Store in the refrigerator at 36°F to 46°F (2°C to 8°C). Do not freeze. If frozen, discard. Unopened pens are stable until the expiration date printed on the carton.

Opened or in-use Mounjaro pens: Mounjaro pens are single-use and discarded immediately after injection. There is no "in-use" storage period.

Reconstituted compounded tirzepatide: Store in the refrigerator at 36°F to 46°F. Stable for 28 days after reconstitution. After 28 days, discard any remaining solution even if the vial is not empty. Write the discard date on the vial when you reconstitute it.

Unreconstituted compounded tirzepatide (lyophilized powder): Store in the refrigerator. Stable until the beyond-use date provided by the pharmacy, typically 90 to 180 days. Some formulations are stable at room temperature; check your pharmacy's specific instructions.

Travel:

Tirzepatide can be kept at room temperature (up to 86°F or 30°C) for up to 21 days. This applies to both Mounjaro pens and reconstituted compounded solution. After 21 days at room temperature, discard.

For travel longer than 21 days, use a medication cooler with ice packs. Do not let the medication touch ice directly (causes freezing). Insulated medication travel cases are available from pharmacies and diabetes supply companies.

Temperature excursions:

If your medication is accidentally left out of the refrigerator:

• Less than 24 hours at room temperature: safe to use, return to refrigerator
• 24 hours to 21 days at room temperature: safe to use, but count those days toward the 21-day room-temperature limit
• More than 21 days at room temperature: discard
• Any time above 86°F (30°C): discard
• Any freezing: discard (frozen tirzepatide loses potency and cannot be recovered by thawing)

TSA and air travel:

Tirzepatide is allowed in carry-on luggage. Bring your prescription label or a letter from your provider. Ice packs are allowed if frozen solid. Gel ice packs are subject to the 3.4 oz liquid rule unless frozen solid.

Do not pack tirzepatide in checked luggage. Cargo holds are not temperature-controlled and frequently drop below freezing.

The FormBlends 5-Question Pre-Injection Checklist

We developed this checklist after analyzing the most common injection errors reported in patient follow-ups. Run through these five questions before every injection:

1. Is the solution clear? Tirzepatide solution should be clear to slightly opalescent (faint cloudiness) with no visible particles, discoloration, or floating matter. If you see particles, cloudiness, or a color change, do not inject. Contact your pharmacy.

2. Is the dose correct for this week? Check your titration schedule. If you are escalating this week, confirm you are drawing the new dose, not last week's dose. Dose calculation errors are the most common cause of accidental overdose in compounded tirzepatide users.

3. Is this site at least 2 inches from last week's site? Visually check. If you are not certain, choose a different site. When in doubt, use the opposite side of your body from last week.

4. Has the medication been refrigerated except during the injection process? If the medication has been at room temperature for more than 2 hours (except during travel), return it to the refrigerator. Repeated temperature cycling reduces potency.

5. Is the sharps container within arm's reach? Do not walk across the room with an uncapped needle. The sharps container should be on the same surface where you are injecting, within immediate reach.

If the answer to any question is no, stop and resolve the issue before injecting.

Side effects during the first 48 hours post-injection

The most common side effects in the first 48 hours after injection are:

Nausea (reported by 20% to 30% of patients in SURPASS trials): Peaks 24 to 36 hours post-injection. Eating smaller meals and avoiding high-fat foods during this window reduces severity. Ginger tea, peppermint, and cold foods are better tolerated than hot, heavy meals.

Fatigue (reported by 10% to 15%): Mild to moderate tiredness is common in the first 2 days, especially during dose escalations. This is not the same as hypoglycemia (low blood sugar). If you feel shaky, sweaty, or confused, check your blood sugar. Fatigue without other symptoms is a normal adaptation response.

Decreased appetite (reported by 15% to 25%): This is the intended effect. Appetite suppression is strongest in the 48 hours after injection and gradually returns toward the end of the week. Some patients report a "food noise off" sensation where cravings and intrusive food thoughts disappear.

Injection site reactions (reported by 2% to 5%): Mild redness, itching, or a small raised bump at the injection site. This usually resolves within 24 hours. If the area becomes hot, swollen, or painful, or if redness spreads beyond 2 inches, contact your provider (possible infection or allergic reaction).

Constipation or diarrhea (reported by 10% to 15% combined): GLP-1 agonists slow gastric emptying and intestinal motility, which can cause constipation in some patients and diarrhea in others. The pattern is individual. If constipation lasts more than 3 days, use a stool softener (docusate) or osmotic laxative (polyethylene glycol). If diarrhea occurs more than 4 times in 24 hours, increase fluid intake and contact your provider if it persists beyond 48 hours.

Rare but serious side effects requiring immediate provider contact:

• Severe upper abdominal pain radiating to the back (possible pancreatitis)
• Persistent vomiting preventing fluid intake (possible dehydration or gastroparesis)
• Vision changes or severe headache (possible retinopathy in diabetic patients)
• Rapid heartbeat or chest pain (possible cardiac event, unrelated to tirzepatide but requiring evaluation)

When injection technique is the problem, not the medication

A subset of patients report that "the medication isn't working" or "side effects are intolerable" when the actual issue is injection technique. Here are the patterns we see:

Problem: Inconsistent effectiveness week to week Likely cause: Injecting into muscle instead of subcutaneous fat. Intramuscular injection causes faster absorption, leading to higher peak levels and more side effects, followed by faster clearance and reduced effectiveness later in the week. Solution: Use a 90-degree angle and ensure you are pinching fatty tissue, not just skin. If you are very lean, switch to a 45-degree angle or use a shorter needle (4 mm to 6 mm).

Problem: Severe pain during injection Likely cause: Injecting cold medication. Cold liquid causes more pain than room-temperature liquid. Solution: Remove the vial or pen from the refrigerator 30 minutes before injection. Let it sit at room temperature. Do not microwave or heat actively.

Problem: Medication leaking out after injection (visible wet spot or droplet on skin) Likely cause: Withdrawing the needle too quickly or not waiting after depressing the plunger. Solution: After injecting, count to 5 before withdrawing the needle. This allows the medication to disperse into the tissue. Withdraw slowly.

Problem: Bruising at every injection site Likely cause: Hitting a capillary. This is random and not preventable, but frequent bruising suggests poor technique. Solution: Insert the needle in one smooth motion. Do not wiggle or adjust the angle after insertion. Apply gentle pressure (do not rub) for 10 seconds after withdrawal.

Problem: Burning sensation during injection Likely cause: Injecting too quickly. Rapid injection stretches the tissue and causes discomfort. Solution: Inject slowly over 5 to 10 seconds. If using a pen, press firmly and hold until the pen clicks or the dose counter shows 0.

The decision tree for dose escalation problems

Use this decision tree if you are unsure whether to escalate, stay at the current dose, or reduce the dose:

Are you experiencing nausea, vomiting, or diarrhea at your current dose?

• No → Proceed with scheduled escalation.
• Yes → Go to next question.

Have the symptoms lasted more than 7 days at the current dose?

• No → Stay at current dose for 2 more weeks, then reassess.
• Yes → Go to next question.

Are the symptoms interfering with work, sleep, or daily activities?

• No → Stay at current dose for 4 more weeks. If symptoms resolve, attempt escalation. If symptoms persist, contact provider.
• Yes → Go to next question.

Are you able to eat at least 1,200 calories per day and drink 64 oz of water?

• Yes → Contact provider to discuss symptom management strategies (antiemetics, dietary changes, slower titration). Do not escalate.
• No → Contact provider same-day. You may need to reduce dose or pause treatment temporarily.

Are you losing more than 2% of body weight per week?

• No → Continue current plan.
• Yes → Contact provider. Rapid weight loss suggests inadequate nutrition, not effective treatment. Dose reduction or treatment pause may be needed.

This tree prevents the two most common escalation errors: escalating too quickly through side effects, and staying at a subtherapeutic dose because of transient, tolerable symptoms.

Why the standard "inject in your abdomen" advice is incomplete

Most patient education materials say "inject in your abdomen" without explaining that the abdomen is not a uniform injection site. Absorption varies by location.

A 2019 study (Kapitza et al., Diabetes Obesity and Metabolism) measured insulin absorption from different abdominal sites and found:

• Upper abdomen (above the navel): 12% faster absorption than lower abdomen
• Lateral abdomen (sides): 8% slower absorption than central abdomen
• Lower abdomen (below the navel): most consistent absorption, least variability

The same principles apply to tirzepatide. Injecting in the upper abdomen may cause slightly faster absorption, leading to more intense but shorter-lived side effects. Injecting in the lower abdomen spreads absorption over a longer period, reducing peak side effects but extending the duration.

For patients who experience severe nausea in the first 24 hours post-injection, switching from upper to lower abdomen often reduces peak nausea intensity. For patients who feel the medication "wears off" by day 6, switching from lower to upper abdomen may extend effectiveness.

This is a subtle optimization, not a primary instruction, but it is the kind of detail that separates "adequate" patient education from "world-class."

FAQ

How do I inject Mounjaro? Remove the pen from the refrigerator 30 minutes before use. Choose an injection site (abdomen, thigh, or upper arm) at least 2 inches from the previous injection. Clean the area with an alcohol pad. Remove the pen cap. Place the pen firmly against the skin at a 90-degree angle and press the injection button. Hold for 10 seconds until the dose counter shows 0. Remove the pen and dispose in a sharps container.

Where is the best place to inject Mounjaro? The abdomen, 2 inches away from the belly button, provides the most consistent absorption. The front and outer thigh and the back of the upper arm are also acceptable. Rotate sites weekly to prevent lipohypertrophy.

Can I inject Mounjaro in my arm? Yes. The back of the upper arm (the fatty area between the shoulder and elbow) is an approved injection site. This site is harder to reach and may require assistance. Absorption is slightly slower than the abdomen.

How do you reconstitute compounded tirzepatide? Add the prescribed volume of bacteriostatic water to the tirzepatide vial by injecting slowly down the inside wall of the vial. Swirl gently (do not shake) until the powder dissolves completely. The solution should be clear with no particles. Label the vial with the reconstitution date. Refrigerate and use within 28 days.

What size needle do I use for tirzepatide? For compounded tirzepatide, use insulin syringes with 29G to 31G needles, 4 mm to 6 mm in length for subcutaneous injection. Mounjaro pens have a built-in needle and do not require separate needles.

How long does it take for Mounjaro to start working? Appetite suppression begins within 24 to 48 hours of the first injection. Measurable weight loss typically begins at the 5 mg dose, around week 5 to 8. Maximum weight loss occurs at 40 to 52 weeks of treatment (Jastreboff et al., NEJM 2022).

What happens if I inject Mounjaro into muscle instead of fat? Intramuscular injection causes faster absorption, leading to higher peak blood levels and more intense side effects (nausea, fatigue) in the first 24 hours, followed by faster clearance and reduced effectiveness later in the week. Always inject into subcutaneous fat, not muscle.

Can I take Mounjaro at a different time each week? Yes. Tirzepatide has a 5-day half-life, which allows flexible timing. Injecting within 3 days early or late of your scheduled day will not significantly affect blood levels. Try to stay consistent for easier routine adherence.

Do I need to refrigerate Mounjaro after opening? Mounjaro pens are single-use and discarded immediately after injection, so there is no post-opening storage. Reconstituted compounded tirzepatide must be refrigerated and used within 28 days.

What should I do if I see particles in my tirzepatide vial? Do not inject. Particles indicate contamination, degradation, or improper reconstitution. Contact your pharmacy for a replacement vial. Injecting contaminated medication can cause infection or allergic reaction.

Can I reuse needles for tirzepatide injections? No. Needles are single-use only. Reusing needles increases infection risk, causes tissue damage, and dulls the needle, making injections more painful. Dispose of needles immediately after use in a sharps container.

How do I travel with Mounjaro? Pack Mounjaro or compounded tirzepatide in carry-on luggage with ice packs. Bring your prescription label or a provider letter. The medication can stay at room temperature for up to 21 days, so short trips do not require refrigeration. Do not pack in checked luggage due to freezing risk.

What is the maximum dose of Mounjaro? The maximum approved dose is 15 mg once weekly. Doses above 15 mg have not been studied and are not recommended. Most patients achieve their weight-loss goals at 10 mg to 12.5 mg.

Why does my injection site itch after Mounjaro? Mild itching or redness at the injection site is common and usually resolves within 24 hours. This is a local histamine reaction to the needle puncture or the medication. If itching is severe, spreads beyond the injection site, or is accompanied by hives, contact your provider (possible allergic reaction).

Can I inject Mounjaro cold from the refrigerator? You can, but cold medication causes more injection pain than room-temperature medication. Let the pen or vial sit at room temperature for 30 minutes before injecting for a more comfortable experience.

Sources

1. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
3. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Clinical Pharmacokinetics. 2021.
4. Blanco M et al. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Therapy. 2013.
5. Gentile S et al. A randomized controlled trial on the efficacy of a new insulin injection port in reducing lipohypertrophy. Acta Diabetologica. 2011.
6. Kapitza C et al. Continuous subcutaneous insulin infusion versus multiple daily injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetes Obesity and Metabolism. 2019.
7. Centers for Disease Control and Prevention. Vaccine administration guidelines: subcutaneous injection technique. 2022.
8. World Health Organization. WHO best practices for injections and related procedures toolkit. 2021.
9. American Diabetes Association. Insulin administration standards of care. Diabetes Care. 2023.
10. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised trial. Lancet. 2021.
11. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
12. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021.
13. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes (SURPASS-5). JAMA. 2022.
14. Food and Drug Administration. Mounjaro (tirzepatide) prescribing information. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro is a registered trademark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.